bit.bio
Excedr clients can book a free, no-commitment consultation to see how bit.bio cells can accelerate research and drug discovery.
Products & Services
bit.bio engineers deterministically programmed human iPSC-derived cells for research, drug discovery, and cell therapy. Its products include wild-type cells, disease models, and CRISPR-ready cells, offering unmatched consistency and scalability.
Powered by Nobel Prize-winning science, bit.bio’s opti-ox™ technology enables the single-step conversion of iPSCs into any desired human cell type within days, achieving exceptional purity and industrial scale. The company’s ioCells portfolio includes ioWild Type Cells, ioDisease Model Cells, and ioCRISPR-Ready Cells. I
ts txCell pipeline targets metabolism, endocrinology, immunology, and neurology, with lead candidate bbHEP01 (encapsulated allogeneic txHepatocytes) in development for acute liver diseases. Additionally, bit.bio collaborates with BlueRock Therapeutics, a Bayer AG subsidiary, to advance regulatory T cell (Treg)-based therapies.
Through its technology and pipeline, bit.bio is unlocking new possibilities for novel cures.
Learn more about bit.bio's ioCells.
Discover more about bit.bio's cell therapy pipeline.
Tenant Brochure
bit.bio is a synthetic biology company democratizing human cells to advance biomedical research and enable transformative treatments.
It utilizes opti-ox technology to deterministically program induced pluripotent stem cells (iPSCs)into any desired human cell type in a single step, within days at an industrial scale, with exceptional purity and consistency.
